ROIV Roivant Sciences Ltd.

Roivant Sciences (NASDAQ:ROIV) CEO Matthew Gline outlined the company’s priorities for the next 12 months, including the launch of LISRAYA, upcoming clinical data for brepocitinib and Immunovant’s IMVT-1402, and expansion of its pulmonary hypertension program. Gline said Roivant recently received a

Roivant Sciences Ltd. (NASDAQ:ROIV) shares jumped about 17% after the company reported positive mid-stage results for mosliciguat, its experimental treatment for pulmonary hypertension associated with interstitial lung disease (PH-ILD). The readout gives Roivant (NASDAQ:ROIV) another late-stage pipeline opportunity shortly after the company won U.S. approval for Lisraya, its treatment for adults with dermatomyositis. READ ALSO: […]

(Updates with economic data, recent oil price movements, world markets' overview, and corporate stoc

Roivant Sciences (NASDAQ:ROIV) said its majority-owned subsidiary Immunovant will discontinue development of IMVT-1402, also known as imeroprubart, in cutaneous lupus erythematosus after a proof-of-concept study failed to meet its primary endpoint. The randomised, double-blind, placebo-controlled trial enrolled 57 adults with cutaneous lupus erythematosus.

Roivant Sciences Ltd. (NASDAQ:ROIV) may be entering the most important phase of its business, as its pipeline begins to move from clinical development to commercialization. Stifel initiated coverage of Roivant with a Buy rating and a $51 price target on September 16. The target implied a roughly 29% upside from the stock price at that […]

Roivant Sciences (NasdaqGS: ROIV) reported positive Phase 2 PHocus trial results for mosliciguat in PH-ILD patients. The study showed statistically significant and clinically meaningful changes in pulmonary vascular resistance and six-minute walk distance measures. Management highlighted the PHocus findings at recent scientific conference presentations focused on pulmonary hypertension and interstitial lung disease. There is more to Roivant than the PHocus mosliciguat data investors are...

Roivant Sciences Ltd. (NASDAQ:ROIV) shares surged 18% on September 8 after the biotech company reported strong Phase 2 results for an experimental treatment for pulmonary hypertension. The positive topline results from the Phase 2 PHocus trial of Mosliciguat provide an important clinical validation for one of the company’s most promising pipeline assets. The candidate drug […]

The healthcare team dive into the latest data and emerging trends from the ESC Congress and ERS Congress.

Companies In The Article Are:QCOM,ROIV,BE and NVS

Investors rewarded three very different catalysts spanning artificial intelligence, biotechnology, and energy.

Roivant Sciences Ltd. (NASDAQ:ROIV) soared to a new all-time high on Tuesday after reporting stellar results from the clinical trial of its treatment candidate for pulmonary hypertension associated with interstitial lung disease (PH-ILD). In intra-day trading, the stock jumped to its highest price of $42.50 before trimming gains to end the session just up by […]

Biotech stocks Roivant and Pharvaris hit records Tuesday on "blowout" and "bull case" results for lung and swelling disease treatments.

Roivant Sciences reported positive Phase 2 results for its experimental lung disease drug, Mosliciguat, while Pharvaris’ oral therapy met the main goal of a Phase 3 study of preventive treatment for hereditary angioedema.

Roivant Sciences (ROIV) shares soared 19% after the company said its Pulmovant unit's phase 2 PHocus

Roivant Sciences stock was surging after the biotech reported success in a mid-stage trial of its experimental lung-and-heart artery drug, mosliciguat.

Pulmovant, a clinical-stage biotech and Roivant (NASDAQ:ROIV) company, on Tuesday shared topline data from its Phase 2 PHocus clinical trial evaluating mosliciguat for pulmonary hypertension associated with interstitial lung disease (PH-ILD). PH-ILD occurs when scarring and inflammation in the lungs restrict blood flow through the pulmonary arteries, raising blood pressure within the lungs. Presented at the European Respiratory Society International Congress 2026, the data highlight meaningful c

(Updates with economic data, recent oil price movement, world markets' overview and corporate stock

Roivant’s Mosliciguat reduced pulmonary vascular resistance by 56.3% compared with placebo after 16 weeks.

Roivant Sciences (NASDAQ:ROIV) shares rose 22. 0% in premarket trading after its Pulmovant subsidiary reported topline results from the Phase 2 PHocus study of mosliciguat in patients with pulmonary hypertension associated with interstitial lung disease, or PH-ILD.

Roivant Sciences Ltd. (NASDAQ:ROIV) and Priovant Therapeutics have moved quickly to commercialize Lisraya following its FDA approval for dermatomyositis. The partners launched the daily pill immediately and set a list price of $35,000 for a 30-day supply. The price illustrates the potential value of introducing the first targeted oral treatment for a rare condition with […]

Roivant Sciences Ltd. (NASDAQ:ROIV) and partner Priovant Therapeutics have secured FDA approval for Lisraya, the first oral treatment for dermatomyositis, which is a rare condition that causes painful skin rashes and progressive muscle weakness. The approval gives patients an oral alternative in a disease with limited targeted treatment options. It also creates a new commercial […]

Roivant Sciences (NASDAQ:ROIV) said the U.S. Food and Drug Administration has approved LISRAYA, its once-daily oral therapy for adults with dermatomyositis, and that the drug has already entered commercial launch. Matt Gline, Roivant’s CEO, called the approval a significant milestone for patients w

Roivant Sciences reported past first-quarter 2026 results, with sales of US$1.44 million versus US$2.17 million a year earlier and a narrower net loss of US$189.84 million, reducing basic loss per share from US$0.33 to US$0.26. The combination of lower revenue yet improved loss per share highlights Roivant’s ongoing effort to manage costs while progressing its inflammation and immunology portfolio. We’ll now examine how this combination of reduced sales and a smaller quarterly net loss could...

Why Roivant Sciences Stock Is In Focus After First Quarter Results Roivant Sciences (NasdaqGS:ROIV) is in focus after reporting first quarter results for the period ended June 30, 2026. Sales were US$1.44 million, while the company reported a net loss of US$189.84 million. The loss from continuing operations translated into a basic loss per share of US$0.26. Investors are now weighing how these figures, together with the updated loss profile, fit into the broader story for this clinical stage...

Moby summary of Roivant Sciences Ltd.'s Q1 2026 earnings call

Roivant Sciences (NASDAQ:ROIV) said it expects a busy second half of 2026, with a potential launch of brepocitinib in dermatomyositis, several clinical readouts and additional regulatory discussions across its pipeline. Chief Executive Officer Matt Gline characterized the quarter as relatively quie

Roivant Sciences Ltd (ROIV) reports robust financials and key clinical milestones, including the brepocitinib launch and Moderna settlement, while navigating pipeline uncertainties.

Montes Archimedes Acquisition (ROIV) delivered earnings and revenue surprises of 0.00% and -35.48%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Fortrea Holdings Inc. (FTRE) delivered earnings and revenue surprises of +27.78% and +4.62%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Arbutus expects to receive around $179 million from Moderna.

Wall Street expects sales to soar as several commercial launches approach.